Continued use of Atorvostatin in sepsis

Phase 2

Completed

• Conditions: Sepsis / infection in patients taking statin therapy; Blood - Studies of infection and infectious agents

• Registration Number: ACTRN12605000756628
• Lead Sponsor: Dr Peter Kruger, Intensive Care Specialist, Princess Alexandra Hospital, Brisbane

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-11-18
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

All patients with sepsis syndrome who are on statin therapy at the time of admisison to hospital are eligable for inclusion.

Exclusion Criteria

Pregnancy, acute liver failure or chronic liver disease ( more than Childs B), patients who are moribund and not expected to survive 24 hrs, patients with rhabdomyolysis or myopathy of any cause. Patients in whom any enteral intake will clearly not be possible within 72 hours.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of severe sepsis[during hospital admission]

Secondary Outcome Measures

Name	Time	Method
28 Day mortality[post hospital admission date];Biological markers of inflammation , lipid profile , oxidative stress.[during hospital admission]